Label-free screening assays: a strategy for finding better drug candidates

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev.62(2),265–304 (2010).Crossref, Medline, CAS, Google Scholar
• 2  Smith RG, Sestili MA. Methods for ligand-receptor assays in clinical chemistry. Clin. Chem.26(5),543–550 (1980).Crossref, Medline, CAS, Google Scholar
• 3  Hart HE, Greenwald EB. Scintillation proximity assay (SPA)– a new method of immunoassay. Direct and inhibition mode detection with human albumin and rabbit antihuman albumin. Mol. Immunol.16(4),265–267 (1979).Crossref, Medline, CAS, Google Scholar
• 4  Udenfriend S, Gerber LD, Brink L, Spector S. Scintillation proximity radioimmunoassay utilizing 125I-labeled ligands. Proc. Natl Acad. Sci. USA82(24),8672–8676 (1985).Crossref, Medline, CAS, Google Scholar
• 5  Hoffman R, Cameron L. Characterization of a scintillation proximity assay to detect modulators of transforming growth factor α (TGFα) binding. Anal. Biochem.203,70–75 (1992).Crossref, Medline, CAS, Google Scholar
• 6  Jessop RA. Imaging proximity assays. Proc.SPIE3259,228–233 (1998).Crossref, CAS, Google Scholar
• 7  Watson J, Selkirk JV, Brown AM. Development of Flashplate^TM technology to measure [35s]gtpys binding to chinese hamster ovary cell membranes expressing the cloned human 5-HTIB receptor. J. Biomol. Screen.3,101–105 (1998).Crossref, CAS, Google Scholar
• 8  Carpenter JW, Laethem C, Hubbard FR et al. Configuring radioligand receptor binding assays for HTS using scintillation proximity assay technology. Methods Mol. Biol.190,31–49 (2002).Medline, CAS, Google Scholar
• 9  Glickman JF, Schmid A, Ferrand S. Scintillation proximity assays in high-throughput screening. Assay Drug Dev.Technol.6(3),433–455 (2008).Crossref, Medline, CAS, Google Scholar
• 10  Schroeder KS, Neagle BD. FLIPR: a new instrument for accurate, high throughput optical screening. J. Biomolec. Screen.1(2),75–80 (1996).Crossref, CAS, Google Scholar
• 11  Glaser V. An interview with Kirk S. Schroeder, President, Essen Instruments. Assay Drug Develop. Technol.1,3–8 (2002).Crossref, Medline, Google Scholar
• 12  Ullman EF, Kirakossian H, Singh S et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl Acad. Sci. USA91(12),5426–5430 (1994).Crossref, Medline, CAS, Google Scholar
• 13  Glickman JF, Wu X, Mercuri R et al. A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J. Biomol. Screen.7(1),3–10 (2002).Crossref, Medline, CAS, Google Scholar
• 14  Golla R, Seethala R. A homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists. J. Biomol. Screen.7(6),515–525 (2002).Crossref, Medline, CAS, Google Scholar
• 15  Michael S, Auld D, Klumpp C et al. A robotic platform for quantitative high-throughput screening. Assay Drug. Dev. Technol.6(5),637–657 (2008).Crossref, Medline, CAS, Google Scholar
• 16  Hook DJ. Team building and leadership in the successful implementation of automation for high-throughput screening. J. Auto. Chem.18(4),131–134 (1996).Crossref, Medline, CAS, Google Scholar
• 17  Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov.8(12),959–968 (2009).Crossref, Medline, CAS, Google Scholar
• 18  Kola I. The state of innovation in drug development. Clin. Pharmacol. Ther.83(2),227–230 (2008).Crossref, Medline, CAS, Google Scholar
• 19  Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat. Biotechnol.24(7),805–815 (2006).Crossref, Medline, CAS, Google Scholar
• 20  Hollinger MA. Introduction to Pharmacology (2nd Edition) Taylor and Francis, NY, USA, 6 (2003).Google Scholar
• 21  Kirschner MH. All Medicines are Poison! Author House, IN, USA, 4 (2009).Google Scholar
• 22  European research group of Morgan Stanley. Laboratory Equipment Magazine 12 March (2010).Google Scholar
• 23  Huggett B. Still strapped for cash. Nat. Biotech.27(6),493 (2009).Crossref, Medline, CAS, Google Scholar
• 24  Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature425(6954),191–196 (2003).Crossref, Medline, CAS, Google Scholar
• 25  Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for treatment of Type 2 diabetes. Nature450,712–716 (2007).Crossref, Medline, CAS, Google Scholar
• 26  Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem.280(17),17187–17195 (2005).Crossref, Medline, CAS, Google Scholar
• 27  Kaeberlein M, McDonagh T, Heltweg B et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem.280(17),17038–17045 (2005).Crossref, Medline, CAS, Google Scholar
• 28  Pacholec M, Bleasdale JE, Chrunyk B et al. SRT1720, SRT2183, SRT1460, and Resveratrol are not direct activators of SIRT1. J. Biol. Chem.285,8340–8351 (2010).Crossref, Medline, CAS, Google Scholar
• 29  Beher D, Wu J, Cumine S et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des.74(6),619–624 (2009).Crossref, Medline, CAS, Google Scholar
• 30  Yan SF, King FJ, He Y, Caldwell JS, Zhou Y. Learning from the data: mining of large high-throughput screening databases. J. Chem. Inf. Model46(6),2381–2395 (2006).Crossref, Medline, CAS, Google Scholar
• 31  Xie XQ, Chen JZ. Data mining a small-molecule drug screening representative subset from NIH PubChem. J. Chem. Inf. Model48(3),465–475 (2008).Crossref, Medline, CAS, Google Scholar
• 32  Kostenis E, Waelbroeck M, Milligan G. Techniques: promiscuous Ga proteins in basic research and drug discovery. Trends Pharmacol. Sci.26(11),595–602 (2005).Crossref, Medline, CAS, Google Scholar
• 33  Zehender H, Le Goff F, Lehmann N, Filipuzzi I, Mayr LM. SpeedScreen: the ‘missing link’ between genomics and lead discovery. J. Biomol. Screen.9,498–505 (2004).Crossref, Medline, CAS, Google Scholar
• 34  Brown N, Zehender H, Azzaoui K, Schuffenhauer A, Mayr LM, Jacoby E. A chemoinformatics analysis of hit lists obtained from high-throughput affinity-selection screening. J. Biomol. Screen.11(2),123–130 (2006).Crossref, Medline, Google Scholar
• 35  Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. A general technique to rank protein–ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem. Soc.126(47),15495–15503 (2004).Crossref, Medline, CAS, Google Scholar
• 36  Coburn CA, Stachel SJ, Li YM et al. Identification of a small molecule nonpeptide active site β-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J. Med. Chem.47(25),6117–6119 (2004).Crossref, Medline, CAS, Google Scholar
• 37  Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem. Soc.126(47),15495–15503 (2004).Crossref, Medline, CAS, Google Scholar
• 38  Whitehurst CE, Nazef N, Annis DA et al. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry. J. Biomol. Screen.11(2),194–207 (2006).Crossref, Medline, Google Scholar
• 39  Annis DA, Shipps GW Jr, Deng Y et al. Method for quantitative protein-ligand affinity measurements in compound mixtures. Anal. Chem.79(12),4538–4542 (2007).Crossref, Medline, CAS, Google Scholar
• 40  Zheng H, Loh HH, Law PY. Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life62(2),112–119 (2010).Medline, CAS, Google Scholar
• 41  Groebe DR. Screening for positive allosteric modulators of biological targets. Drug Discov. Today11(13–14),632–639 (2006).Crossref, Medline, CAS, Google Scholar
• 42  Groebe DR. In search of negative allosteric modulators of biological targets. Drug Discov. Today14(1–2),41–49 (2009).Crossref, Medline, CAS, Google Scholar
• 43  Roddy TP, Horvath CR, Stout SJ et al. Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal. Chem.79(21),8207–8213 (2007).Crossref, Medline, CAS, Google Scholar
• 44  Zhang JH, Roddy TP, Ho PI et al. Assay development and screening of human DGAT1 inhibitors with an LC/MS-based assay: application of mass spectrometry for large-scale primary screening. J. Biomol. Screen.15(6),695–702 (2010) (Epub).Crossref, Medline, CAS, Google Scholar
• 45  Quercia AK, LaMarr WA, Myung J, Ozbal CC, Landro JA, Lumb KJ. High-throughput screening by mass spectrometry: comparison with the scintillation proximity assay with a focused-file screen of AKT1/PKB a. J. Biomol. Screen.12(4),473–480 (2007).Crossref, Medline, CAS, Google Scholar
• 46  Ozbal CC, LaMarr WA, Linton JR et al. High-throughput screening via mass spectrometry: a case study using acetylcholinesterase. Assay Drug Dev. Technol.2(4),373–381 (2004).Crossref, Medline, Google Scholar
• 47  Forbes CD, Toth JG, Ozbal CC et al. High-throughput mass spectrometry screening for inhibitors of phosphatidylserine decarboxylase. J. Biomol. Screen.12(5),628–634 (2007).Crossref, Medline, CAS, Google Scholar
• 48  Soulard P, McLaughlin M, Stevens J et al. Development of a high-throughput screening assay for stearoyl-coa desaturase using rat liver microsomes, deuterium labeled stearoyl-coa and mass spectrometry. Analytica Chimica Acta.627(1),105–111 (2008).Crossref, Medline, CAS, Google Scholar
• 49  Jonas M, LaMarr WA, Ozbal C. Mass spectrometry in high-throughput screening: a case study on acetyl-coenzyme a carboxylase using RapidFire – mass spectrometry (RF-MS). Comb. Chem. High Throughput Screen.12(8),752–759 (2009).Crossref, Medline, CAS, Google Scholar
• 50  Lim KB, Ozbal CC, Kassel DB. Development of a high-throughput online solid-phase extraction/tandem mass spectrometry method for cytochrome P450 inhibition screening. J. Biomol. Screen.15(4),447–452 (2010).Crossref, Medline, CAS, Google Scholar
• 51  Motlekar N, Diamond SL, Napper AD. Evaluation of an orthogonal pooling strategy for rapid high-throughput screening of proteases. Assay Drug Dev. Technol.6(3),395–405 (2008).Crossref, Medline, CAS, Google Scholar
• 52  Langsdorf EF, Malikzay A, Lamarr WA et al. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay. J. Biomol. Screen.15(1),52–61 (2010).Crossref, Medline, CAS, Google Scholar
• 53  Cummings MD, Farnum MA, Nelen MI. Universal screening methods and applications of ThermoFluor. J. Biomol. Screen.11(7),854–863 (2006).Crossref, Medline, CAS, Google Scholar
• 54  Clare JJ. Targeting ion channels for drug discovery. Discov. Med.9(46),253–260 (2010).Medline, Google Scholar
• 55  Milligan G, Kostenis E. Heterotrimeric G-proteins: a short history. Br. J. Pharmacol.147(Suppl. 1),S46–S55 (2006).Crossref, Medline, CAS, Google Scholar
• 56  Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci.28(8),390–396 (2007).Crossref, Medline, CAS, Google Scholar
• 57  Zheng H, Loh HH, Law PY. Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life62(2),112–119 (2010).Medline, CAS, Google Scholar
• 58  Prather PL, Martin NA, Breivogel CS, Childers SR. Activation of cannabinoid receptors in rat brain by WIN 55212–2 produces coupling to multiple G protein α-subunits with different potencies. Mol. Pharmacol.57(5),1000–1010 (2000).Medline, CAS, Google Scholar
• 59  Houston DB, Howlett AC. Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal.10(9),667–674 (1998).Crossref, Medline, CAS, Google Scholar
• 60  Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov.9(5),373–386 (2010).▪▪ Discusses the roles of biased ligands in receptor bioactivity and as therapeutics.Crossref, Medline, CAS, Google Scholar
• 61  Ferré S, Goldberg SR, Lluis C, Franco R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology56(Suppl 1),226–234 (2009).Crossref, Medline, CAS, Google Scholar
• 62  Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov. Today.14(7–8),413–419 (2009).Crossref, Medline, CAS, Google Scholar
• 63  Traynor J. Regulator of G protein-signaling proteins and addictive drugs. Ann. NY Acad. Sci.1187,341–352 (2010).Crossref, Medline, CAS, Google Scholar
• 64  Maudsley S, Martin B, Luttrell LM. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr. Alzheimer Res.4(1),3–19 (2007).Crossref, Medline, CAS, Google Scholar
• 65  Galandrin S, Oligny-Longpré G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci.28(8),423–430 (2007).▪ Discusses the impact of complex receptor biology on the drug discovery process.Crossref, Medline, CAS, Google Scholar
• 66  Banerjee P, Franz B, Bhunia AK. Mammalian cell-based sensor system. Adv. Biochem. Eng. Biotechnol.117,21–55 (2010).Medline, CAS, Google Scholar
• 67  Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med.11,e3 (2009).Crossref, Medline, Google Scholar
• 68  Idris AI, van ‘t Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med.11(7),774–779 (2005).Crossref, Medline, CAS, Google Scholar
• 69  Idris AI, Sophocleous A, Landao-Bassonga E, van’t Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology.149(11),5619–5626 (2008).Crossref, Medline, CAS, Google Scholar
• 70  Ofek O, Karsak M, Leclerc N et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl Acad. Sci. USA103(3),696–701 (2006).Crossref, Medline, CAS, Google Scholar
• 71  Lunn CA, Fine J, Rojas-Triana A et al. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss. Immunopharmacol. Immunotoxicol.29(3–4),387–401 (2007).Crossref, Medline, CAS, Google Scholar
• 72  Lozano-Ondoua AN, Wright C, Vardanyan A et al. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci.86(17–18),646–653 (2010).Crossref, Medline, CAS, Google Scholar
• 73  Geng D, Xu Y, Yang H et al. Protection against titanium particle induced osteolysis by cannabinoid receptor 2 selective antagonist. Biomaterials31(8),1996–2000 (2010).Crossref, Medline, CAS, Google Scholar
• 74  Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 55212–2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler.10(2),158–164 (2004).Crossref, Medline, CAS, Google Scholar
• 75  Maresz K, Pryce G, Ponomarev ED et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med.13(4),492–497 (2007).Crossref, Medline, CAS, Google Scholar
• 76  Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J. Leukoc. Biol.78(1),231–238 (2005).Crossref, Medline, CAS, Google Scholar
• 77  Palazuelos J, Davoust N, Julien B et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem.283(19),13320–13329 (2008).Crossref, Medline, CAS, Google Scholar
• 78  Lunn CA, Reich EP, Fine JS et al. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br. J. Pharmacol.153(2),226–239 (2008).Crossref, Medline, CAS, Google Scholar
• 79  Lunn CA. Updating the chemistry and biology of cannabinoid CB(2) receptor-specific inverse agonists. Curr. Top. Med. Chem.10(8),768–778 (2010).Crossref, Medline, CAS, Google Scholar
• 80  Cotton M, Claing A. G protein-coupled receptors stimulation and the control of cell migration. Cell Signal.21(7),1045–1053 (2009).▪▪ Describes downstream effects of receptor activation on cell migration, with a focus on receptor bioactivity.Crossref, Medline, CAS, Google Scholar
• 81  DeFea K. β-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br. J. Pharmacol.153(Suppl. 1),S298–S309 (2008).▪▪ Describes downstream effects of receptor activation on cell migration, with focus on contribution of β-arrestins.Crossref, Medline, CAS, Google Scholar
• 82  Ganguly S, Pucadyil TJ, Chattopadhyay A. Actin cytoskeleton-dependent dynamics of the human serotonin1A receptor correlates with receptor signaling. Biophys. J.95(1),451–463 (2008).Crossref, Medline, CAS, Google Scholar
• 83  Johnson EN. High throughput screening follow-up studies using physiologically relevant cells. Am. Drug Discov.3(2),12–22 (2007).Google Scholar
• 84  Cunningham BT, Li P, Schulz S et al. Label-free assays on the BIND system. J. Biomol. Screen.9(6),481–490 (2004).Crossref, Medline, CAS, Google Scholar
• 85  Fang Y, Ferrie AM, Li G. Probing cytoskeleton modulation by optical biosensors. FEBS Lett.579(19),4175–4180 (2005).Crossref, Medline, CAS, Google Scholar
• 86  Verdonk E, Johnson K, McGuinness R et al. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev. Technol.4(5),609–619 (2006).Crossref, Medline, CAS, Google Scholar
• 87  Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev. Technol.2(4),363–372 (2004).Crossref, Medline, CAS, Google Scholar
• 88  Lee PH, Gao A, van Staden C et al. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed G protein-coupled receptors. Assay Drug Dev.Technol.6,83–94 (2008).Crossref, Medline, Google Scholar
• 89  Yu N, Atienza JM, Bernard J et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal. Chem.78,35–43 (2006).Crossref, Medline, CAS, Google Scholar
• 90  Peters MF, Knappenberger KS, Wilkins D et al. Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J. Biomol. Screen.12,312–319 (2007).Crossref, Medline, CAS, Google Scholar
• 91  Peters MF, Scott CW. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J. Biomol. Screen.14,246–255 (2009).Crossref, Medline, CAS, Google Scholar
• 92  Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW. Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev. Technol.8(2),219–227 (2010).▪ Investigators provide direct comparison of multiple label-free biosensor platforms.Crossref, Medline, CAS, Google Scholar
• 93  Du Y, Li Z, Li L et al. Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. J. Recept. Signal. Trans.29(3–4),182–194 (2009).Crossref, Medline, CAS, Google Scholar
• 94  Fang Y, Ferrie AM. Label-free optical biosensor for ligand-directed functional selectivity acting on β(2) adrenoceptor in living cells. FEBS Lett.582(5),558–564 (2008).Crossref, Medline, CAS, Google Scholar
• 95  Dodgson K, Gedge L, Murray DC, Coldwell M. A 100K well screen for a muscarinic receptor using the Epic^® label-free system – a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors. J. Recept. Signal Trans.29(3–4),163–172 (2009).▪▪ Investigator provides direct evidence of the potential benefits of label-free biosensors as a screening tool for seven transmembrane receptor targets.Crossref, Medline, CAS, Google Scholar
• 96  Begley S, Carmichael M. Desperately seeking cures. Newsweek. May 24 & 31, 38–42 (2010).Google Scholar
• 97  Rathore R, Pribil P, Corr JJ, Seibel WL, Evdokimov A, Greis KD. Multiplex enzyme assays and inhibitor screening by mass spectrometry. J. Biomol. Screen.15(8),1001–1007 (2010) (Epub).Crossref, Medline, CAS, Google Scholar
• 98  Bowen BP, Northen TR. Dealing with the unknown: metabolomics and metabolite atlases. J. Am. Soc. Mass. Spectrom.21(9),1471–1476 (2010).Crossref, Medline, CAS, Google Scholar
• 99  Young NL, Plazas-Mayorca MD, Garcia BA. Systems-wide proteomic characterization of combinatorial post-translational modification patterns. Expert Rev. Proteomics.7(1),79–92 (2010).Crossref, Medline, CAS, Google Scholar
• 100  Wang D, Bodovitz S. Single cell analysis: the new frontier in ‘omics’. Trends Biotechnol.28(6),281–290 (2010). (Epub).Crossref, Medline, CAS, Google Scholar
• 101  Baxter MA, Rowe C, Alder J et al. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res.5(1),4–22 (2010).Crossref, Medline, CAS, Google Scholar
• 102  Murata M, Tohyama S, Fukuda K. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery. Pharmacol. Ther.126(2),109–118 (2010).Crossref, Medline, CAS, Google Scholar
• 103  Phillips BW, Crook JM. Pluripotent human stem cells: a novel tool in drug discovery. BioDrugs24(2),99–108 (2010).Crossref, Medline, CAS, Google Scholar
• 104  Sano Y, Shimizu F, Abe M et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood–brain barrier function. J. Cell. Physiol.225(2),519–528 (2010).Crossref, Medline, CAS, Google Scholar
• 105  Gu Y, Li H, Miki J et al. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp. Cell Res.312(6),831–843 (2006).Crossref, Medline, CAS, Google Scholar
• 106  Brandt S. TERT over-expression affects the growth of myocardial tissue derived from mouse embryonic stem cells. Differentiation,79(1),1–8 (2010).Crossref, Medline, CAS, Google Scholar
• 107  Cheung PY, Deng W, Man C et al. Genetic alterations in a telomerase-immortalized human esophageal epithelial cell line: implications for carcinogenesis. Cancer Lett.293(1),41–51 (2010).Crossref, Medline, CAS, Google Scholar
• 108  SRU Biosystems. Introducing the BIND^® Scanner: low cell number applications in cytotoxicity, chemotaxis and differentiation. Presented at: SBS 16th Annual Conference & Exhibition, Phoenix, AZ, USA, 13 April 2010.Google Scholar
• 109  Huang WE, Li M, Jarvis RM, Goodacre R, Banwart SA. Shining light on the microbial world the application of Raman microspectroscopy. Adv. Appl. Microbiol.70,153–186 (2010).Crossref, Medline, CAS, Google Scholar
• 110  Wachsmann-Hogiu S, Weeks T, Huser T. Chemical analysis in vivo and in vitro by Raman spectroscopy – from single cells to humans. Curr. Opin. Biotechnol.20(1),63–73 (2009).Crossref, Medline, CAS, Google Scholar
• 111  Bleicher KH, Böhm HJ, Müller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov.2(5),369–378 (2003).Crossref, Medline, CAS, Google Scholar
• 112  Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches. Drug Discov. Today11(15–16),741–748 (2006).Crossref, Medline, Google Scholar
• 113  Feng BY, Shoichet BK. Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J. Med. Chem.49(7),2151–2154 (2006).Crossref, Medline, CAS, Google Scholar
• 114  Jadhav A, Ferreira RS, Klumpp C et al. Quantitative analyses of aggregation, autofluorescence and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem.53(1),37–51 (2010).Crossref, Medline, CAS, Google Scholar
• 201  Duncan DE. Pharma and biotech: is there love? Fortune, 10 May 2010. http://money.cnn.com/2010/05/10/news/companies/pharma_biotech_marriage.fortune/Google Scholar
• 202  Herper M. Why Glaxo Bought Sirtris. FORBES, April 24 (2008) www.forbes.com/2008/04/23/pharmacuticals-sirtris-glaxosmithkline-biz-healthcare-cx_mh_0424glaxo.htmlGoogle Scholar